{"id":745291,"date":"2016-12-05T19:30:00","date_gmt":"2016-12-05T19:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/keytruda-pembrolizumab-treatment-results-in-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma-chl-presented-at-58th-annual-meeting-of-the-american-society-of-hematology\/"},"modified":"2025-11-07T01:25:29","modified_gmt":"2025-11-07T06:25:29","slug":"keytruda-pembrolizumab-treatment-results-in-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma-chl-presented-at-58th-annual-meeting-of-the-american-society-of-hematology","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/keytruda-pembrolizumab-treatment-results-in-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma-chl-presented-at-58th-annual-meeting-of-the-american-society-of-hematology\/","title":{"rendered":"KEYTRUDA\u00ae (pembrolizumab) Treatment Results in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) Presented at 58th Annual Meeting of the American Society of Hematology"},"content":{"rendered":"<p class=\"bwalignc\">       Data from Pivotal KEYNOTE-087 Trial Show Overall Response Rate (ORR)        of 69.0 Percent and Complete Remission Rate (CRR) of 22.4 Percent     <\/p>\n<p class=\"bwalignc\">       With More than Two Years of Follow-up, Findings from KEYNOTE-013 Show        ORR of 58 Percent and CRR of 19 Percent with Responses of 12 Months or        Greater in 70 Percent of Responding Patients     <\/p>\n<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      announced today updated findings evaluating KEYTRUDA<sup>\u00ae<\/sup><br \/>\n      (pembrolizumab), the company\u2019s anti-PD-1 therapy, in two trials of<br \/>\n      patients with relapsed or refractory classical Hodgkin lymphoma (cHL).<br \/>\n      In the KEYNOTE-087 and KEYNOTE-013 trials, KEYTRUDA demonstrated overall<br \/>\n      response rates (ORR) of 69.0 percent and 58 percent, respectively.<br \/>\n      KEYNOTE-013, which had a median follow up of 29 months, showed responses<br \/>\n      of 12 months or greater in 70 percent of patients who responded to<br \/>\n      therapy. These findings will be presented today at the 58<sup>th<\/sup><br \/>\n      Annual Meeting of the American Society of Hematology (ASH).<br \/>\n      Additionally, data from these trials supported the recently announced<br \/>\n      regulatory filing with the U.S. Food and Drug Administration.\n    <\/p>\n<p>\n      \u201cAs the data mature from these two studies, we continue to be encouraged<br \/>\n      by the response rates, including complete remission and durable<br \/>\n      responses, in patients with relapsed or refractory classical Hodgkin<br \/>\n      lymphoma,\u201d said Dr. Roger Dansey, senior vice president and therapeutic<br \/>\n      area head, oncology late-stage development, Merck Research Laboratories.\n    <\/p>\n<p>\n      The KEYTRUDA clinical development program includes more than 30 tumor<br \/>\n      types in nearly 400 clinical trials, including more than 200 trials that<br \/>\n      combine KEYTRUDA with other cancer treatments. For hematologic<br \/>\n      malignancies specifically, Merck is conducting broad immuno-oncology<br \/>\n      research assessing the role of monotherapy and combination regimens with<br \/>\n      KEYTRUDA (pembrolizumab). The hematology program includes nearly 40<br \/>\n      ongoing studies \u2013 including company sponsored, investigator sponsored<br \/>\n      and collaborative studies; several of these are registration-enabling<br \/>\n      trials.\n    <\/p>\n<p>\n      \u201cWhen patients with classical Hodgkin lymphoma do not respond to<br \/>\n      standard of care chemotherapy or autologous stem cell&nbsp;transplantation,<br \/>\n      the cancer is difficult to successfully treat. For these patients, who<br \/>\n      are often in their 20s and 30s, the need to identify new treatment<br \/>\n      options is urgent,\u201d said Dr. Craig Moskowitz, clinical director,<br \/>\n      division of hematologic oncology, Memorial Sloan Kettering Cancer<br \/>\n      Center. \u201cThese data are promising and show that pembrolizumab may<br \/>\n      provide meaningful clinical benefit to patients with this disease.\u201d\n    <\/p>\n<p>\n      <b>Results from KEYNOTE-087<\/b>\n    <\/p>\n<p>\n      Results from the KEYNOTE-087 trial will be presented in an oral<br \/>\n      presentation by Dr. Moskowitz at 5 p.m. PST (Location: San Diego<br \/>\n      Convention Center, Room 6B) (Abstract #1107).\n    <\/p>\n<p>\n      KEYNOTE-087 is a multicenter, open-label, multi-cohort,<br \/>\n      activity-estimating phase 2 trial evaluating KEYTRUDA (200 mg fixed dose<br \/>\n      every three weeks) monotherapy in patients with relapsed or refractory<br \/>\n      cHL across three cohorts. The primary endpoints include overall safety,<br \/>\n      tolerability, and ORR (per blinded independent central review, BICR);<br \/>\n      secondary endpoints include ORR (per investigator review), duration of<br \/>\n      response (DOR), progression-free survival (PFS) and overall survival<br \/>\n      (OS). The patient cohorts are intended to assess the outcome measures<br \/>\n      in: patients whose disease progressed following an autologous stem cell<br \/>\n      transplantation and subsequent treatment with brentuximab vedotin, an<br \/>\n      antibody drug conjugate (Cohort 1); patients who failed salvage<br \/>\n      chemotherapy and were ineligible for a transplant and whose disease<br \/>\n      progressed following treatment with brentuximab vedotin (Cohort 2); and<br \/>\n      patients whose disease progressed after transplant and who did not<br \/>\n      receive brentuximab vedotin after transplant (Cohort 3).\n    <\/p>\n<p>\n      Across all 210 enrolled patients,<i> <\/i>the ORR was 69.0 percent<br \/>\n      (n=145; 95% CI, 62.3-75.2) by BICR, and the complete remission rate was<br \/>\n      22.4 percent (n=47; 95% CI, 16.9-28.6). Across all cohorts, 93 percent<br \/>\n      of patients experienced a decrease in tumor burden (n=192).\n    <\/p>\n<p>\n      By cohort, the data showed:\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        In Cohort 1, (n=69), ORR was 73.9 percent (n=51; 95% CI, 61.9-83.7) \u2013<br \/>\n        with complete remissions in 21.7 percent (n=15; 95% CI, 12.7-33.3) and<br \/>\n        partial remissions in 52.2 percent (n=36; 95% CI, 39.8-64.4) of<br \/>\n        patients. An additional 15.9 percent of patients had stable disease<br \/>\n        (n=11; 95% CI, 8.2-26.7) and 7.2 percent of patients had progressive<br \/>\n        disease (n=5; 95% CI, 2.4-16.1). Additionally, 82.2 percent of<br \/>\n        responding patients had a response of six months or greater.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        In Cohort 2 (n=81), ORR was 64.2 percent (n=52; 95% CI, 52.8-74.6) \u2013<br \/>\n        with complete remissions in 24.7 percent (n=20; 95% CI, 15.8-35.5) and<br \/>\n        partial remissions in 39.5 percent (n=32; 95% CI, 28.8-51.0) of<br \/>\n        patients. An additional 12.3 percent of patients had stable disease<br \/>\n        (n=10; 95% CI, 6.1-21.5) and 21.0 percent of patients had progressive<br \/>\n        disease (n=17; 95% CI, 12.7-31.5). Additionally, 70 percent of<br \/>\n        responding patients had a response of six months or greater.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        In Cohort 3 (n=60), ORR was 70.0 percent (n=42; 95% CI, 56.8-81.2) \u2013<br \/>\n        with complete remissions in 20.0 percent (n=12; 95% CI, 10.8-32.3) and<br \/>\n        partial remissions in 50.0 percent (n=30; 95% CI, 36.8-63.2) of<br \/>\n        patients. An additional 16.7 percent of patients had stable disease<br \/>\n        (n=10; 95% CI, 8.3-28.5) and 13.3 percent of patients had progressive<br \/>\n        disease (n=8; 95% CI, 5.9-24.6). Additionally, 75.6 percent of<br \/>\n        responding patients had a response of six months or greater.\n      <\/li>\n<\/ul>\n<p>\n      Results also included an analysis of patients with primary refractory<br \/>\n      disease (n=73), defined as failure to achieve complete or partial<br \/>\n      response to first-line treatment. In this patient population, the ORR<br \/>\n      (per BICR) was 79.5 percent (n=58; 95% CI, 68.4-88.0). Additionally, an<br \/>\n      ORR of 67.8 percent (95% CI, 59.6-75.3) was reported in patients who<br \/>\n      relapsed after three or more lines of prior therapy (n=99\/146).\n    <\/p>\n<p>\n      The safety profile of KEYTRUDA (pembrolizumab) was consistent with that<br \/>\n      observed in previously reported studies.&nbsp;The most common<br \/>\n      treatment-related adverse events were hypothyroidism (12.4%), pyrexia<br \/>\n      (10.5%), fatigue (9.0%), rash (7.6%), diarrhea (7.1%), headache (6.2%),<br \/>\n      nausea (5.7%), cough (5.7%) and neutropenia (5.2%). The most common<br \/>\n      grade 3 or 4 treatment-related adverse events were neutropenia (2.4%),<br \/>\n      diarrhea (1.0%) and dyspnea (1.0%). Immune-mediated adverse events<br \/>\n      included pneumonitis (2.9%), hyperthyroidism (2.9%), colitis (1.0%) and<br \/>\n      myositis (1.0%). There were nine discontinuations because of<br \/>\n      treatment-related adverse events and no treatment-related deaths.\n    <\/p>\n<p>\n      <b>Results from KEYNOTE-013<\/b>\n    <\/p>\n<p>\n      Results from the KEYNOTE-013 trial will be presented in an oral<br \/>\n      presentation by Dr. Philippe Armand, medical oncologist, Dana-Farber<br \/>\n      Cancer Institute at 5:15 p.m. PST (Location: San Diego Convention<br \/>\n      Center, Room 6B) (Abstract #1108).\n    <\/p>\n<p>\n      KEYNOTE-013 is an ongoing, multicenter, non-randomized, phase 1b trial<br \/>\n      of approximately 200 patients&nbsp;evaluating the safety, tolerability, and<br \/>\n      efficacy of KEYTRUDA (pembrolizumab) monotherapy in patients with blood<br \/>\n      cancers, including myelodysplastic syndromes, multiple myeloma,<br \/>\n      classical Hodgkin lymphoma, mediastinal large B cell lymphoma and<br \/>\n      certain other non-Hodgkin\u2019s lymphoma (or lymphomata). The primary<br \/>\n      endpoints of the study include overall safety, tolerability, and<br \/>\n      complete remission rate (as measured by International Harmonization<br \/>\n      Project Response Criteria); secondary endpoints include ORR, DOR, PFS,<br \/>\n      and OS.\n    <\/p>\n<p>\n      Data from a cohort of the study evaluated KEYTRUDA monotherapy at 10<br \/>\n      mg\/kg every two weeks in patients with relapsed or refractory cHL who<br \/>\n      had progressed on or after treatment with brentuximab vedotin after<br \/>\n      failure of autologous stem cell transplant, or who were<br \/>\n      transplant-ineligible. Response was assessed at week 12 and every 8<br \/>\n      weeks thereafter according to the International Harmonization Project<br \/>\n      2007 criteria.\n    <\/p>\n<p>\n      Across all 31 patients enrolled in the KEYNOTE-013 classical Hodgkin<br \/>\n      lymphoma cohort, the ORR was 58 percent (n=18; 95% CI, 39-76) by BICR,<br \/>\n      and the complete remission rate was 19 percent (n=6; 95% CI, 8-38).<br \/>\n      Thirty-nine percent of patients achieved partial remission (n=12; 95%<br \/>\n      CI, 22-58) and 23 percent had stable disease (n=7; 95% CI, 10-41). The<br \/>\n      median duration of response was not yet reached (range 0.0+ to 26.1+<br \/>\n      months) and 70 percent of responding patients had a response of 12<br \/>\n      months or greater. The median duration of follow-up was 29 months.\n    <\/p>\n<p>\n      Measured by BICR, median PFS was 11.4 months (4.9-27.8). The six-month<br \/>\n      PFS rate was 66 percent and the 12-month rate was 48 percent. Median OS<br \/>\n      was not reached. Six-month and 12-month OS rates were 100 percent and 87<br \/>\n      percent, respectively.\n    <\/p>\n<p>\n      The safety profile of KEYTRUDA was consistent with that observed in<br \/>\n      previously reported studies.&nbsp;The most common treatment-related adverse<br \/>\n      events were diarrhea (19%), hypothyroidism (13%), pneumonitis (13%),<br \/>\n      nausea (13%), fatigue (10%) and dyspnea (10%). The most common grade 3<br \/>\n      or 4 treatment-related adverse events were colitis (3%), axillary pain<br \/>\n      (3%), AST increased (3%), joint swelling (3%), nephrotic syndrome back<br \/>\n      pain (3%) and dyspnea (3%). Adverse events leading to discontinuation<br \/>\n      were nephrotic syndrome (grade 3), interstitial lung disease (grade 2)<br \/>\n      and pneumonitis (grade 2). There were no treatment-related deaths.\n    <\/p>\n<p>\n      <b>About Hodgkin Lymphoma<\/b>\n    <\/p>\n<p>\n      Hodgkin lymphoma is a type of lymphoma that develops in the white blood<br \/>\n      cells, called lymphocytes, which are part of the immune system. Hodgkin<br \/>\n      lymphoma can start almost anywhere \u2013 most often in lymph nodes in the<br \/>\n      upper part of the body, with the most common sites being in the chest,<br \/>\n      neck or under the arms. In 2016, it is estimated that more than 8,500<br \/>\n      people will be diagnosed with Hodgkin lymphoma in the U.S.; cHL accounts<br \/>\n      for about 95 percent of all cases of Hodgkin lymphoma in developed<br \/>\n      countries.\n    <\/p>\n<p>\n      <b>About KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (pembrolizumab)<\/b>\n    <\/p>\n<p>\n      KEYTRUDA is a humanized monoclonal antibody that works by increasing the<br \/>\n      ability of the body\u2019s immune system to help detect and fight tumor<br \/>\n      cells. KEYTRUDA blocks the interaction between PD-1 and its ligands,<br \/>\n      PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both<br \/>\n      tumor cells and healthy cells.\n    <\/p>\n<p>\n      KEYTRUDA is administered as an intravenous infusion over 30 minutes<br \/>\n      every three weeks for the approved indications. KEYTRUDA for injection<br \/>\n      is supplied in a 100 mg single use vial.\n    <\/p>\n<p>\n      <b>KEYTRUDA<\/b> <b>Indications and Dosing<\/b>\n    <\/p>\n<p>\n      <i>Melanoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with unresectable or<br \/>\n      metastatic melanoma at a dose of 2 mg\/kg every three weeks until disease<br \/>\n      progression or unacceptable toxicity.\n    <\/p>\n<p>\n      <i>Lung Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the first-line treatment of patients with<br \/>\n      metastatic non-small cell lung cancer (NSCLC) whose tumors have high<br \/>\n      PD-L1 expression [tumor proportion score (TPS) \u226550%] as determined by an<br \/>\n      FDA-approved test, with no EGFR or ALK genomic tumor aberrations.\n    <\/p>\n<p>\n      KEYTRUDA is also indicated for the treatment of patients with metastatic<br \/>\n      NSCLC whose tumors express PD-L1 (TPS \u22651%) as determined by an<br \/>\n      FDA-approved test, with disease progression on or after<br \/>\n      platinum-containing chemotherapy. Patients with EGFR or ALK genomic<br \/>\n      tumor aberrations should have disease progression on FDA-approved<br \/>\n      therapy for these aberrations prior to receiving KEYTRUDA.\n    <\/p>\n<p>\n      In metastatic NSCLC, KEYTRUDA is administered at a fixed dose of 200 mg<br \/>\n      every three weeks until disease progression, unacceptable toxicity, or<br \/>\n      up to 24 months in patients without disease progression.\n    <\/p>\n<p>\n      <i>Head and Neck Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA (pembrolizumab) is indicated for the treatment of patients with<br \/>\n      recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)<br \/>\n      with disease progression on or after platinum-containing chemotherapy.<br \/>\n      This indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. In HNSCC, KEYTRUDA is<br \/>\n      administered at a fixed dose of 200 mg every three weeks until disease<br \/>\n      progression, unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <b>Selected Important Safety Information for KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup>&nbsp;<b>(pembrolizumab)<\/b>\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated pneumonitis, including fatal cases.<br \/>\n      Pneumonitis occurred in 94 (3.4%) of 2799 patients receiving KEYTRUDA,<br \/>\n      including Grade 1 (0.8%), 2 (1.3%), 3 (0.9%), 4 (0.3%), and 5 (0.1%)<br \/>\n      pneumonitis, and occurred more frequently in patients with a history of<br \/>\n      prior thoracic radiation (6.9%) compared to those without (2.9%).<br \/>\n      Monitor patients for signs and symptoms of pneumonitis. Evaluate<br \/>\n      suspected pneumonitis with radiographic imaging. Administer<br \/>\n      corticosteroids for Grade 2 or greater pneumonitis. Withhold KEYTRUDA<br \/>\n      for Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4 or<br \/>\n      recurrent Grade 2 pneumonitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated colitis. Colitis occurred in 48<br \/>\n      (1.7%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.4%), 3<br \/>\n      (1.1%), and 4 (&lt;0.1%) colitis. Monitor patients for signs and symptoms<br \/>\n      of colitis. Administer corticosteroids for Grade 2 or greater colitis.<br \/>\n      Withhold KEYTRUDA for Grade 2 or 3; permanently discontinue KEYTRUDA for<br \/>\n      Grade 4 colitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated hepatitis. Hepatitis occurred in 19<br \/>\n      (0.7%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.1%), 3<br \/>\n      (0.4%), and 4 (&lt;0.1%) hepatitis. Monitor patients for changes in liver<br \/>\n      function. Administer corticosteroids for Grade 2 or greater hepatitis<br \/>\n      and, based on severity of liver enzyme elevations, withhold or<br \/>\n      discontinue KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA can cause hypophysitis. Hypophysitis occurred in 17 (0.6%) of<br \/>\n      2799 patients receiving KEYTRUDA, including Grade 2 (0.2%), 3 (0.3%),<br \/>\n      and 4 (&lt;0.1%) hypophysitis. Monitor patients for signs and symptoms of<br \/>\n      hypophysitis (including hypopituitarism and adrenal insufficiency).<br \/>\n      Administer corticosteroids and hormone replacement as clinically<br \/>\n      indicated. Withhold KEYTRUDA for Grade 2; withhold or discontinue for<br \/>\n      Grade 3 or 4 hypophysitis.\n    <\/p>\n<p>\n      KEYTRUDA (pembrolizumab) can cause thyroid disorders, including<br \/>\n      hyperthyroidism, hypothyroidism, and thyroiditis. Hyperthyroidism<br \/>\n      occurred in 96 (3.4%) of 2799 patients receiving KEYTRUDA, including<br \/>\n      Grade 2 (0.8%) and 3 (0.1%) hyperthyroidism. Hypothyroidism occurred in<br \/>\n      237 (8.5%) of 2799 patients receiving KEYTRUDA, including Grade 2 (6.2%)<br \/>\n      and 3 (0.1%) hypothyroidism. The incidence of new or worsening<br \/>\n      hypothyroidism was higher in patients with HNSCC occurring in 28 (15%)<br \/>\n      of 192 patients with HNSCC, including Grade 3 (0.5%) hypothyroidism.<br \/>\n      Thyroiditis occurred in 16 (0.6%) of 2799 patients receiving KEYTRUDA,<br \/>\n      including Grade 2 (0.3%) thyroiditis. Monitor patients for changes in<br \/>\n      thyroid function (at the start of treatment, periodically during<br \/>\n      treatment, and as indicated based on clinical evaluation) and for<br \/>\n      clinical signs and symptoms of thyroid disorders. Administer replacement<br \/>\n      hormones for hypothyroidism and manage hyperthyroidism with thionamides<br \/>\n      and beta-blockers as appropriate. Withhold or discontinue KEYTRUDA for<br \/>\n      Grade 3 or 4 hyperthyroidism.\n    <\/p>\n<p>\n      KEYTRUDA can cause type 1 diabetes mellitus, including diabetic<br \/>\n      ketoacidosis, which have been reported in 6 (0.2%) of 2799 patients.<br \/>\n      Monitor patients for hyperglycemia or other signs and symptoms of<br \/>\n      diabetes. Administer insulin for type 1 diabetes, and withhold KEYTRUDA<br \/>\n      and administer antihyperglycemics in patients with severe hyperglycemia.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated nephritis. Nephritis occurred in 9<br \/>\n      (0.3%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.1%), 3<br \/>\n      (0.1%), and 4 (&lt;0.1%) nephritis. Monitor patients for changes in renal<br \/>\n      function. Administer corticosteroids for Grade 2 or greater nephritis.<br \/>\n      Withhold KEYTRUDA for Grade 2; permanently discontinue KEYTRUDA for<br \/>\n      Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      KEYTRUDA can cause other clinically important immune-mediated adverse<br \/>\n      reactions. For suspected immune-mediated adverse reactions, ensure<br \/>\n      adequate evaluation to confirm etiology or exclude other causes. Based<br \/>\n      on the severity of the adverse reaction, withhold KEYTRUDA and<br \/>\n      administer corticosteroids. Upon improvement to Grade 1 or less,<br \/>\n      initiate corticosteroid taper and continue to taper over at least 1<br \/>\n      month. Based on limited data from clinical studies in patients whose<br \/>\n      immune-related adverse reactions could not be controlled with<br \/>\n      corticosteroid use, administration of other systemic immunosuppressants<br \/>\n      can be considered. Resume KEYTRUDA when the adverse reaction remains at<br \/>\n      Grade 1 or less following corticosteroid taper. Permanently discontinue<br \/>\n      KEYTRUDA for any Grade 3 immune-mediated adverse reaction that recurs<br \/>\n      and for any life-threatening immune-mediated adverse reaction.\n    <\/p>\n<p>\n      The following clinically significant immune-mediated adverse reactions<br \/>\n      occurred in less than 1% (unless otherwise indicated) of 2799 patients:<br \/>\n      arthritis (1.5%), exfoliative dermatitis, bullous pemphigoid, rash<br \/>\n      (1.4%), uveitis, myositis, Guillain-Barr\u00e9 syndrome, myasthenia gravis,<br \/>\n      vasculitis, pancreatitis, hemolytic anemia, and partial seizures arising<br \/>\n      in a patient with inflammatory foci in brain parenchyma.\n    <\/p>\n<p>\n      KEYTRUDA (pembrolizumab) can cause severe or life-threatening<br \/>\n      infusion-related reactions, which have been reported in 6 (0.2%) of 2799<br \/>\n      patients. Monitor patients for signs and symptoms of infusion-related<br \/>\n      reactions, including rigors, chills, wheezing, pruritus, flushing, rash,<br \/>\n      hypotension, hypoxemia, and fever. For Grade 3 or 4 reactions, stop<br \/>\n      infusion and permanently discontinue KEYTRUDA.\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA can cause fetal harm when<br \/>\n      administered to a pregnant woman. If used during pregnancy, or if the<br \/>\n      patient becomes pregnant during treatment, apprise the patient of the<br \/>\n      potential hazard to a fetus. Advise females of reproductive potential to<br \/>\n      use highly effective contraception during treatment and for 4 months<br \/>\n      after the last dose of KEYTRUDA.\n    <\/p>\n<p>\n      In KEYNOTE-006, KEYTRUDA was discontinued due to adverse reactions in 9%<br \/>\n      of 555 patients with advanced melanoma; adverse reactions leading to<br \/>\n      discontinuation in more than one patient were colitis (1.4%), autoimmune<br \/>\n      hepatitis (0.7%), allergic reaction (0.4%), polyneuropathy (0.4%), and<br \/>\n      cardiac failure (0.4%). Adverse reactions leading to interruption of<br \/>\n      KEYTRUDA occurred in 21% of patients; the most common (\u22651%) was diarrhea<br \/>\n      (2.5%). The most common adverse reactions with KEYTRUDA vs ipilimumab<br \/>\n      were fatigue (28% vs 28%), diarrhea (26% with KEYTRUDA), rash (24% vs<br \/>\n      23%), and nausea (21% with KEYTRUDA). Corresponding incidence rates are<br \/>\n      listed for ipilimumab only for those adverse reactions that occurred at<br \/>\n      the same or lower rate than with KEYTRUDA.\n    <\/p>\n<p>\n      In KEYNOTE-002, KEYTRUDA was discontinued due to adverse reactions in<br \/>\n      12% of 357 patients with advanced melanoma; the most common (\u22651%) were<br \/>\n      general physical health deterioration (1%), asthenia (1%), dyspnea (1%),<br \/>\n      pneumonitis (1%), and generalized edema (1%). Adverse reactions leading<br \/>\n      to interruption of KEYTRUDA occurred in 14% of patients; the most common<br \/>\n      (\u22651%) were dyspnea (1%), diarrhea (1%), and maculopapular rash (1%). The<br \/>\n      most common adverse reactions with KEYTRUDA vs chemotherapy were fatigue<br \/>\n      (43% with KEYTRUDA), pruritus (28% vs 8%), rash (24% vs 8%),<br \/>\n      constipation (22% vs 20%), nausea (22% with KEYTRUDA), diarrhea (20% vs<br \/>\n      20%), and decreased appetite (20% with KEYTRUDA). Corresponding<br \/>\n      incidence rates are listed for chemotherapy only for those adverse<br \/>\n      reactions that occurred at the same or lower rate than with KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA was discontinued due to adverse reactions in 8% of 682 patients<br \/>\n      with metastatic NSCLC. The most common adverse event resulting in<br \/>\n      permanent discontinuation of KEYTRUDA (pembrolizumab) was pneumonitis<br \/>\n      (1.8%). Adverse reactions leading to interruption of KEYTRUDA occurred<br \/>\n      in 23% of patients; the most common (\u22651%) were diarrhea (1%), fatigue<br \/>\n      (1.3%), pneumonia (1%), liver enzyme elevation (1.2%), decreased<br \/>\n      appetite (1.3%), and pneumonitis (1%). The most common adverse reactions<br \/>\n      (occurring in at least 20% of patients and at a higher incidence than<br \/>\n      with docetaxel) were decreased appetite (25% vs 23%), dyspnea (23% vs<br \/>\n      20%), and nausea (20% vs 18%).\n    <\/p>\n<p>\n      KEYTRUDA was discontinued due to adverse reactions in 17% of 192<br \/>\n      patients with HNSCC. Serious adverse reactions occurred in 45% of<br \/>\n      patients. The most frequent serious adverse reactions reported in at<br \/>\n      least 2% of patients were pneumonia, dyspnea, confusional state,<br \/>\n      vomiting, pleural effusion, and respiratory failure. The most common<br \/>\n      adverse reactions (reported in at least 20% of patients) were fatigue,<br \/>\n      decreased appetite, and dyspnea. Adverse reactions occurring in patients<br \/>\n      with HNSCC were generally similar to those occurring in patients with<br \/>\n      melanoma or NSCLC, with the exception of increased incidences of facial<br \/>\n      edema (10% all Grades; 2.1% Grades 3 or 4) and new or worsening<br \/>\n      hypothyroidism.\n    <\/p>\n<p>\n      It is not known whether KEYTRUDA is excreted in human milk. Because many<br \/>\n      drugs are excreted in human milk, instruct women to discontinue nursing<br \/>\n      during treatment with KEYTRUDA and for 4 months after the final dose.\n    <\/p>\n<p>\n      Safety and effectiveness of KEYTRUDA have not been established in<br \/>\n      pediatric patients.\n    <\/p>\n<p>\n      <b>Our Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck, helping people<br \/>\n      fight cancer is our passion and supporting accessibility to our cancer<br \/>\n      medicines is our commitment. Our focus is on pursuing research in<br \/>\n      immuno-oncology and we are accelerating every step in the journey \u2013 from<br \/>\n      lab to clinic \u2013 to potentially bring new hope to people with cancer.\n    <\/p>\n<p>\n      As part of our focus on cancer, Merck is committed to exploring the<br \/>\n      potential of immuno-oncology with one of the fastest-growing development<br \/>\n      programs in the industry. We are currently executing an expansive<br \/>\n      research program that includes nearly 400 clinical trials evaluating our<br \/>\n      anti-PD-1 therapy across more than 30 tumor types. We also continue to<br \/>\n      strengthen our immuno-oncology portfolio through strategic acquisitions<br \/>\n      and are prioritizing the development of several promising<br \/>\n      immunotherapeutic candidates with the potential to improve the treatment<br \/>\n      of advanced cancers.\n    <\/p>\n<p>\n      For more information about our oncology clinical trials, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;esheet=51472382&amp;newsitemid=20161205006375&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=1&amp;md5=131675006b7d3c3e82e2aa079495cbc5\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For 125 years, Merck has been a global health care leader working to<br \/>\n      help the world be well. Merck is known as MSD outside the United States<br \/>\n      and Canada. Through our prescription medicines, vaccines, biologic<br \/>\n      therapies, and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      health care through far-reaching policies, programs and partnerships.<br \/>\n      For more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51472382&amp;newsitemid=20161205006375&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=18c053d781996096e8a1ab715d1ffee9\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51472382&amp;newsitemid=20161205006375&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=407da5cc1032f016490fe9351c945cad\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51472382&amp;newsitemid=20161205006375&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=6c400ea969deec60d2d052c0c635501d\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51472382&amp;newsitemid=20161205006375&amp;lan=en-US&amp;anchor=YouTube&amp;index=5&amp;md5=446af1be36e482a9095e436a4f6fc3ed\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51472382&amp;newsitemid=20161205006375&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=6&amp;md5=d464d900c2abf8c597a168603f29e899\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2015 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51472382&amp;newsitemid=20161205006375&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=7&amp;md5=11c5b0baa001d1686d1da369a8cf48ce\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for KEYTRUDA (pembrolizumab) at&nbsp;<\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;esheet=51472382&amp;newsitemid=20161205006375&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;index=8&amp;md5=292bdfe351470c80ede8bec1bd15e063\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/b><br \/>\n<\/a><br \/>\n<b>&nbsp;and<\/b>\n    <\/p>\n<p>\n      <b>Patient Information\/Medication Guide for KEYTRUDA at&nbsp;<\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;esheet=51472382&amp;newsitemid=20161205006375&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;index=9&amp;md5=3d911b4135b114792f389747f8d9b13a\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/b><br \/>\n<\/a><br \/>\n<b>.<\/b>\n    <\/p>\n<\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20161205006375r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pamela Eisele, 267-305-3558<br \/>or<br \/>Kim        Hamilton, 908-740-1863<br \/>or<br \/>Investors:<br \/>Teri Loxam,        908-740-1986<br \/>or<br \/>Amy Klug, 908-740-1898     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today updated findings evaluating KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, in two trials of patients with relapsed or refractory classical Hodgkin lymphoma (cHL). In the KEYNOTE-087 and KEYNOTE-013 trials, KEYTRUDA demonstrated overall response rates (ORR) of 69.0 percent and 58 percent, respectively. KEYNOTE-013, which had a median follow up of 29 months, showed responses of 12 months or greater in 70 percent of patients who responded to therapy. These findings will be presented today at the 58 th Annual Meeting of the American Society of Hematology (ASH). Additionally, data from these trials supported the recently announced regulatory filing with the U.S. Food and Drug Administration. \u201cAs the data mature from these two studies, we continue to be encouraged by the response rates, including complete remission and durable responses, in patients with relapsed or refractory classical<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,137,138,55,289],"class_list":["post-745291","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-oncology","tag-oncology-newsroom","tag-prescription-medicine-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>KEYTRUDA\u00ae (pembrolizumab) Treatment Results in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) Presented at 58th Annual Meeting of the American Society of Hematology - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/keytruda-pembrolizumab-treatment-results-in-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma-chl-presented-at-58th-annual-meeting-of-the-american-society-of-hematology\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"KEYTRUDA\u00ae (pembrolizumab) Treatment Results in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) Presented at 58th Annual Meeting of the American Society of Hematology - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today updated findings evaluating KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, in two trials of patients with relapsed or refractory classical Hodgkin lymphoma (cHL). In the KEYNOTE-087 and KEYNOTE-013 trials, KEYTRUDA demonstrated overall response rates (ORR) of 69.0 percent and 58 percent, respectively. KEYNOTE-013, which had a median follow up of 29 months, showed responses of 12 months or greater in 70 percent of patients who responded to therapy. These findings will be presented today at the 58 th Annual Meeting of the American Society of Hematology (ASH). Additionally, data from these trials supported the recently announced regulatory filing with the U.S. Food and Drug Administration. \u201cAs the data mature from these two studies, we continue to be encouraged by the response rates, including complete remission and durable responses, in patients with relapsed or refractory classical\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/keytruda-pembrolizumab-treatment-results-in-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma-chl-presented-at-58th-annual-meeting-of-the-american-society-of-hematology\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:25:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"17 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/keytruda-pembrolizumab-treatment-results-in-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma-chl-presented-at-58th-annual-meeting-of-the-american-society-of-hematology\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/keytruda-pembrolizumab-treatment-results-in-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma-chl-presented-at-58th-annual-meeting-of-the-american-society-of-hematology\\\/\",\"name\":\"KEYTRUDA\u00ae (pembrolizumab) Treatment Results in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) Presented at 58th Annual Meeting of the American Society of Hematology - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2016-12-05T19:30:00+00:00\",\"dateModified\":\"2025-11-07T06:25:29+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/keytruda-pembrolizumab-treatment-results-in-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma-chl-presented-at-58th-annual-meeting-of-the-american-society-of-hematology\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/keytruda-pembrolizumab-treatment-results-in-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma-chl-presented-at-58th-annual-meeting-of-the-american-society-of-hematology\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/keytruda-pembrolizumab-treatment-results-in-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma-chl-presented-at-58th-annual-meeting-of-the-american-society-of-hematology\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"KEYTRUDA\u00ae (pembrolizumab) Treatment Results in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) Presented at 58th Annual Meeting of the American Society of Hematology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"KEYTRUDA\u00ae (pembrolizumab) Treatment Results in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) Presented at 58th Annual Meeting of the American Society of Hematology - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/keytruda-pembrolizumab-treatment-results-in-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma-chl-presented-at-58th-annual-meeting-of-the-american-society-of-hematology\/","og_locale":"en_US","og_type":"article","og_title":"KEYTRUDA\u00ae (pembrolizumab) Treatment Results in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) Presented at 58th Annual Meeting of the American Society of Hematology - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today updated findings evaluating KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, in two trials of patients with relapsed or refractory classical Hodgkin lymphoma (cHL). In the KEYNOTE-087 and KEYNOTE-013 trials, KEYTRUDA demonstrated overall response rates (ORR) of 69.0 percent and 58 percent, respectively. KEYNOTE-013, which had a median follow up of 29 months, showed responses of 12 months or greater in 70 percent of patients who responded to therapy. These findings will be presented today at the 58 th Annual Meeting of the American Society of Hematology (ASH). Additionally, data from these trials supported the recently announced regulatory filing with the U.S. Food and Drug Administration. \u201cAs the data mature from these two studies, we continue to be encouraged by the response rates, including complete remission and durable responses, in patients with relapsed or refractory classical","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/keytruda-pembrolizumab-treatment-results-in-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma-chl-presented-at-58th-annual-meeting-of-the-american-society-of-hematology\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:25:29+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"17 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/keytruda-pembrolizumab-treatment-results-in-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma-chl-presented-at-58th-annual-meeting-of-the-american-society-of-hematology\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/keytruda-pembrolizumab-treatment-results-in-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma-chl-presented-at-58th-annual-meeting-of-the-american-society-of-hematology\/","name":"KEYTRUDA\u00ae (pembrolizumab) Treatment Results in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) Presented at 58th Annual Meeting of the American Society of Hematology - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2016-12-05T19:30:00+00:00","dateModified":"2025-11-07T06:25:29+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/keytruda-pembrolizumab-treatment-results-in-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma-chl-presented-at-58th-annual-meeting-of-the-american-society-of-hematology\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/keytruda-pembrolizumab-treatment-results-in-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma-chl-presented-at-58th-annual-meeting-of-the-american-society-of-hematology\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/keytruda-pembrolizumab-treatment-results-in-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma-chl-presented-at-58th-annual-meeting-of-the-american-society-of-hematology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"KEYTRUDA\u00ae (pembrolizumab) Treatment Results in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) Presented at 58th Annual Meeting of the American Society of Hematology"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"4994081e-ef07-4b27-83cf-a32b05c67a67","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/KEYTRUDA-pembrolizumab-Treatment-Results-in-Patients-with-Relapsed-or-Refractory-Classical-Hodgkin-Lymphoma-cHL-Presented-at-58th-Ann-4BIDO.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745291","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745291\/revisions"}],"predecessor-version":[{"id":3674703,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745291\/revisions\/3674703"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745291"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745291"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}